Major depressive disorder (MDD) continues to be a prevalent disease worldwide. While selective serotonin reuptake inhibitors and other medications continue prescribed, further research has been conducted toward treatment modalities. Within the past decade, ketamine, an N-methyl-d-aspartate receptor antagonist, extensively studied as new for MDD. Recent studies show that ketamine at subanestheti...